US FDA Extends Exelixis Cancer Drug Review
The FDA has extended its review of Exelixis experimental colorectal cancer drug combination by three months. The regulator will now make a decision by March 2027 following updated safety submissions.
Insights:
The United States Food and Drug Administration extended its review of Exelixis' experimental colorectal cancer drug combination by three months to March 3, 2027. Shares of the company slipped 3.5% during pre-market trading following the announcement. The extension stems from updated safety and efficacy data submitted in response to an agency information request, which regulators classified as a major amendment.
